Merck Sharp & Dohme Llc

This study tested an experimental drug called MK-6194 in 169 adults with non-segmental vitiligo, a condition that causes white patches on the skin. The goal was to see if the drug could reduce the amount of vitiligo on the face compared to a placebo, and to check for side effects…

This study tested whether adding the immunotherapy drug pembrolizumab to precise radiation therapy (SBRT) helps people with early-stage non-small cell lung cancer who cannot have surgery. About 448 adults took part. The trial was stopped early, so results are limited. The goal wa…

This study tested a personalized mRNA vaccine (mRNA-4157) combined with the immunotherapy drug pembrolizumab for people with advanced skin cancer that could be removed by surgery. The goal was to see if the combination worked better than standard treatment or pembrolizumab alone.…

This study tested a once-monthly pill called islatravir to prevent HIV infection in cisgender men and transgender women who have sex with men and are at high risk. About 494 participants took either the monthly pill or an active comparator. The trial was terminated early, but res…

This study tested a new monthly pill (islatravir) to see if it could prevent HIV infection better than a daily pill in 730 women at high risk. The trial was stopped early, so final results are not available. The approach aimed to make HIV prevention easier by reducing how often m…

This study tested whether adding MK-1942 to usual antidepressant medication could help people with treatment-resistant depression. About 99 adults with moderate-to-severe depression who hadn't improved with prior treatments took part. The trial was stopped early, and results are …

This early-stage study tested an experimental drug called MK-6552 in 9 people with narcolepsy type 1, a condition that causes sudden sleep attacks. The goal was to see if the drug is safe and can help people stay awake during the day. Participants took the drug for a week, and re…